{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"REPLOT","nct_id":"NCT06408168","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=replot-nct06408168. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Cohort 1 will include participants who have never received fulvestrant before. The first 15 participants enrolled in Cohort 1 will receive the study drug combination starting on Day 1 of their first treatment cycle. The next 14 participants enrolled in Cohort 1 will begin with fulvestrant alone for at least 12 days and then start repotrectinib sometime between Days 13 and 20 (depending on when their Cycle 1 biopsy is performed). This is done in order to use the biopsy results to study the effects of fulvestrant alone in these patients.","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"About 6 months after the first 15 participants are enrolled, based on their study data, Cohort 2 will begin enrolling up to 29 participants who have received fulvestrant in earlier treatments. Participants in Cohort 2 will receive repotrectinib alone.","label":"Cohort 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-12-08","type":"ACTUAL"},"conditions":["Hormone Receptor-positive Human Epidermal Growth Factor 2-negative","Metastatic Invasive LObular Carcinoma"],"enrollment":{"count":6,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Fulvestrant","otherNames":["Faslodex®"],"type":"DRUG"},{"name":"Repotrectinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-01-05","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-12-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Safety and adverse events (AEs)","timeFrame":"Through study completion; an average of 1 year"}],"references":[],"start_date":{"date":"2024-08-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)","url":"https://clinicaltrials.gov/study/NCT06408168"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/replot-nct06408168"}